Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, and biological activities

被引:49
作者
Di Santo, Roberto [1 ]
Costi, Roberta [1 ]
Roux, Alessandra [1 ]
Miele, Gaetano [1 ]
Crucitti, Giuliana Cuzzucoli [1 ]
Iacovo, Alberto [1 ]
Rosi, Federica [1 ]
Lavecchia, Antonio [2 ]
Marinelli, Luciana [2 ]
Di Giovanni, Carmen [2 ]
Novellino, Ettore [2 ]
Palmisano, Lucia [3 ]
Andreotti, Mauro [3 ]
Amici, Roberta [3 ]
Galluzzo, Clementina Maria [3 ]
Nencioni, Lucia [4 ]
Palamara, Anna Teresa [4 ]
Pommier, Yves [5 ]
Marchand, Christophe [5 ]
机构
[1] Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy
[2] Univ Naples Federico 2, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy
[3] Ist Super Sanita, Dipartimento Farmaco, I-00161 Rome, Italy
[4] Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, I-00185 Rome, Italy
[5] NCI, NIH, Ctr Canc Res, Mol Phys Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1021/jm8001422
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Novel quinolinonyl diketo acids were designed to obtain integrase (IN) inhibitors selectively active against the strand transfer (ST) step of the HIV integration process. Those new compounds are characterized by a single aryl diketo acid (DKA) chain in comparison to 4, a bifunctional diketo acid reported by our group as an anti-IN agent highly potent against both the 3'-processing and ST steps. Compound 6d was the most potent derivative in IN enzyme assays, while 6i showed the highest potency against HIV-1 in acutely infected cells. The selective inhibition of ST suggested the newly designed monofunctional DKAs bind the IN-DNA acceptor site without affecting the DNA donor site.
引用
收藏
页码:4744 / 4750
页数:7
相关论文
共 19 条
[1]  
ALLISON AA, 2007, MOL PHARM, V71, P893
[2]   INHIBITORY EFFECT OF THE POLYANIONIC DRUG SURAMIN ON THE IN-VITRO HIV DNA INTEGRATION REACTION [J].
CARTEAU, S ;
MOUSCADET, JF ;
GOULAOUIC, H ;
SUBRA, F ;
AUCLAIR, C .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 305 (02) :606-610
[3]   Therapies: Confronting the limits of success [J].
Cohen, J .
SCIENCE, 2002, 296 (5577) :2320-2324
[4]   INHIBITION OF HIV-1 INTEGRATION PROTEIN BY AURINTRICARBOXYLIC ACID MONOMERS, MONOMER ANALOGS, AND POLYMER FRACTIONS [J].
CUSHMAN, M ;
SHERMAN, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 185 (01) :85-90
[5]   HIV-1 integrase inhibitors: 2005-2006 update [J].
Dayam, Raveendra ;
Gundla, Rambabu ;
Al-Mawsawi, Laith Q. ;
Neamati, Nouri .
MEDICINAL RESEARCH REVIEWS, 2008, 28 (01) :118-154
[6]   Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, biological activities, and mechanism of action [J].
Di Santo, R ;
Costi, R ;
Roux, A ;
Artico, M ;
Lavecchia, A ;
Marinelli, L ;
Novellino, E ;
Palmisano, L ;
Andreotti, M ;
Amici, R ;
Galluzzo, CM ;
Nencioni, L ;
Palamara, AT ;
Pommier, Y ;
Marchand, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (06) :1939-1945
[7]   Raltegravir (MK-0518): An integrase inhibitor for the treatment of HIV-1 [J].
Evering, Teresa Hope ;
Markowitz, Martin .
DRUGS OF TODAY, 2007, 43 (12) :865-877
[8]   INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS INTEGRASE [J].
FESEN, MR ;
KOHN, KW ;
LETEURTRE, F ;
POMMIER, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) :2399-2403
[9]   INHIBITION OF HIV-1 INTEGRASE BY FLAVONES, CAFFEIC ACID PHENETHYL ESTER (CAPE) AND RELATED-COMPOUNDS [J].
FESEN, MR ;
POMMIER, Y ;
LETEURTRE, F ;
HIROGUCHI, S ;
YUNG, J ;
KOHN, KW .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (03) :595-608
[10]   Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design [J].
Goldgur, Y ;
Craigie, R ;
Cohen, GH ;
Fujiwara, T ;
Yoshinaga, T ;
Fujishita, T ;
Sugimoto, H ;
Endo, T ;
Murai, H ;
Davies, DR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (23) :13040-13043